XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Statements of Operations (Brooklyn ImmunoTherapeutics, LLC) - USD ($)
 2 Months Ended 6 Months Ended 10 Months Ended 12 Months Ended
Dec. 31, 2018
Jun. 30, 2020
Jun. 30, 2019
Nov. 05, 2018
Dec. 31, 2019
Operating Expenses          
Research and development         $ 26,000
Total operating expenses   $ 7,301,000 $ 10,277,000   21,568,000
Loss from operations   (4,153,000) (219,000)   (1,762,000)
Other Expenses          
Total other expense, net         (258,000)
Net loss   (3,241,000) (403,000)   (2,047,000)
Net income attributable to common stockholders   (3,249,000) (411,000)   (2,063,000)
Brooklyn Immunotherapeutics, LLC [Member]          
Operating Expenses          
General and administrative   2,515,198 2,372,333    
Research and development   518,537 1,721,941    
Total operating expenses   3,033,735 4,094,274    
Loss from operations   (3,033,735) (4,094,274)    
Other Expenses          
Interest expense, net   18,923 29,304    
Total other expense, net   (18,923) (29,304)    
Net loss   $ (3,052,658) $ (4,123,578)   8,937,054
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member]          
Operating Expenses          
General and administrative $ 374,267       3,721,490
Research and development 1,621,084       5,156,266
Total operating expenses 1,995,351       8,877,756
Loss from operations (1,995,351)       (8,877,756)
Other Expenses          
Interest expense, net (9,121)       (59,298)
Total other expense, net (9,121)       (59,298)
Net loss $ (2,004,472)       $ (8,937,054)
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor [Member]          
Operating Expenses          
General and administrative       $ 5,351,698  
Research and development       9,078,193  
Total operating expenses       14,429,891  
Loss from operations       (14,429,891)  
Other Expenses          
Interest expense, net       (1,668,711)  
Total other expense, net       (1,668,711)  
Net loss       (16,098,602)  
Deemed dividends on preferred stock       (685,892)  
Gain on extinguishment of preferred stock.       106,560,811  
Net income attributable to common stockholders       $ 89,776,317